Chronic myeloid leukemia: a model for oncology

Leukemias have traditionally served as model systems for research on neoplasia because of the easy availability of cell material from blood and marrow for diagnosis, monitoring and studies on pathophysiology. Beyond these more technical aspects, chronic myeloid leukemia (CML) became the first neopla...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hehlmann, Rüdiger (VerfasserIn) , Berger, Ute (VerfasserIn) , Hochhaus, Andreas (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 02 June 2005
In: Annals of hematology
Year: 2005, Jahrgang: 84, Heft: 8, Pages: 487-497
ISSN:1432-0584
DOI:10.1007/s00277-005-1039-z
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00277-005-1039-z
Volltext
Verfasserangaben:Rüdiger Hehlmann, Ute Berger, Andreas Hochhaus

MARC

LEADER 00000caa a2200000 c 4500
001 1801658412
003 DE-627
005 20220820181827.0
007 cr uuu---uuuuu
008 220512s2005 xx |||||o 00| ||eng c
024 7 |a 10.1007/s00277-005-1039-z  |2 doi 
035 |a (DE-627)1801658412 
035 |a (DE-599)KXP1801658412 
035 |a (OCoLC)1341459929 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Hehlmann, Rüdiger  |d 1941-  |e VerfasserIn  |0 (DE-588)1037003489  |0 (DE-627)751737879  |0 (DE-576)390939463  |4 aut 
245 1 0 |a Chronic myeloid leukemia  |b a model for oncology  |c Rüdiger Hehlmann, Ute Berger, Andreas Hochhaus 
264 1 |c 02 June 2005 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 12.05.2022 
520 |a Leukemias have traditionally served as model systems for research on neoplasia because of the easy availability of cell material from blood and marrow for diagnosis, monitoring and studies on pathophysiology. Beyond these more technical aspects, chronic myeloid leukemia (CML) became the first neoplasia in which the elucidation of the genotype led to a rationally designed therapy of the phenotype. Targeting of the pathogenetically relevant BCR-ABL tyrosine kinase with the selective kinase inhibitor imatinib has induced remissions with almost complete disappearance of any signs and symptoms of CML. This therapeutic success has triggered an intensive search for target structures in other cancers and has led to the development of numerous inhibitors of potential targets, which are being studied in preclinical and clinical trials worldwide. This review deals with some of the recent developments that have evolved since our last review in this journal in 2000 (Hehlmann R, Hochhaus A, Berger U, Reiter A (2000) Current trends in the management of chronic myelogenous leukemia. Ann Hematol 79:345-354). 
650 4 |a Chronic myeloid leukemia 
650 4 |a Evolution to blast crisis 
650 4 |a Imatinib in combination 
650 4 |a Model for oncology 
650 4 |a Targeted therapy 
700 1 |a Berger, Ute  |e VerfasserIn  |0 (DE-588)1255399929  |0 (DE-627)1799635341  |4 aut 
700 1 |a Hochhaus, Andreas  |d 1959-  |e VerfasserIn  |0 (DE-588)1107039339  |0 (DE-627)863321976  |0 (DE-576)474976130  |4 aut 
773 0 8 |i Enthalten in  |t Annals of hematology  |d Berlin : Springer, 1991  |g 84(2005), 8, Seite 487-497  |h Online-Ressource  |w (DE-627)253389852  |w (DE-600)1458429-3  |w (DE-576)072283157  |x 1432-0584  |7 nnas  |a Chronic myeloid leukemia a model for oncology 
773 1 8 |g volume:84  |g year:2005  |g number:8  |g pages:487-497  |g extent:11  |a Chronic myeloid leukemia a model for oncology 
856 4 0 |u https://doi.org/10.1007/s00277-005-1039-z  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220512 
993 |a Article 
994 |a 2005 
998 |g 1107039339  |a Hochhaus, Andreas  |m 1107039339:Hochhaus, Andreas  |d 60000  |d 61200  |e 60000PH1107039339  |e 61200PH1107039339  |k 0/60000/  |k 1/60000/61200/  |p 3  |y j 
998 |g 1255399929  |a Berger, Ute  |m 1255399929:Berger, Ute  |d 60000  |d 61200  |e 60000PB1255399929  |e 61200PB1255399929  |k 0/60000/  |k 1/60000/61200/  |p 2 
998 |g 1037003489  |a Hehlmann, Rüdiger  |m 1037003489:Hehlmann, Rüdiger  |d 60000  |d 61200  |e 60000PH1037003489  |e 61200PH1037003489  |k 0/60000/  |k 1/60000/61200/  |p 1  |x j 
999 |a KXP-PPN1801658412  |e 4133215478 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedDisp":"02 June 2005","dateIssuedKey":"2005"}],"note":["Gesehen am 12.05.2022"],"title":[{"title_sort":"Chronic myeloid leukemia","subtitle":"a model for oncology","title":"Chronic myeloid leukemia"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"id":{"eki":["253389852"],"issn":["1432-0584"],"zdb":["1458429-3"]},"recId":"253389852","physDesc":[{"extent":"Online-Ressource"}],"disp":"Chronic myeloid leukemia a model for oncologyAnnals of hematology","type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title_sort":"Annals of hematology","subtitle":"organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie","title":"Annals of hematology"}],"origin":[{"dateIssuedDisp":"1991-","publisher":"Springer","dateIssuedKey":"1991","publisherPlace":"Berlin ; Heidelberg ; New York"}],"note":["Gesehen am 24.04.2025","Fortsetzung der Druck-Ausgabe","Ungezählte Beil. ab 80.2001: Supplement"],"pubHistory":["62, 1 (Februrary 1991)-"],"part":{"pages":"487-497","year":"2005","text":"84(2005), 8, Seite 487-497","issue":"8","extent":"11","volume":"84"},"titleAlt":[{"title":"Hematology"}],"language":["eng"]}],"recId":"1801658412","name":{"displayForm":["Rüdiger Hehlmann, Ute Berger, Andreas Hochhaus"]},"physDesc":[{"extent":"11 S."}],"id":{"doi":["10.1007/s00277-005-1039-z"],"eki":["1801658412"]},"person":[{"role":"aut","given":"Rüdiger","display":"Hehlmann, Rüdiger","family":"Hehlmann"},{"role":"aut","given":"Ute","family":"Berger","display":"Berger, Ute"},{"given":"Andreas","role":"aut","family":"Hochhaus","display":"Hochhaus, Andreas"}],"language":["eng"]} 
SRT |a HEHLMANNRUCHRONICMYE0220